Results 271 to 280 of about 176,756 (350)

Comparative characteristics of the effectiveness of therapy with PARP inhibitor in patients with primary ovarian cancer in the Tyumen Region in the period from 2019 to 2023

M. S. Kuz'menko, Valeria V. Zhdanova, В. И. Павлова, M. S. Shvedskiy   +3 more
openalex   +2 more sources

Optimizing the integration of modern systemic therapies and advanced radiotherapy techniques in breast cancer management: An expert opinion from the Institut Curie Breast Radiotherapy Group

International Journal of Cancer, Volume 158, Issue 7, Page 1775-1784, 1 April 2026.
Abstract The integration of modern systemic therapies with radiotherapy (RT) represents a promising strategy in breast cancer management, enhancing both locoregional control and systemic disease outcomes. This expert consensus from the Institut Curie Breast Radiotherapy Group focuses exclusively on modern systemic agents, synthesizing current evidence ...
Cezara Cheptea, Pierre Loap, Sofiane Allali, Alain Fourquet, Kim Cao, Youlia Kirova   +5 more
wiley   +1 more source

Phase I study of niraparib with radiotherapy for treatment of metastatic and locally advanced invasive carcinoma of the cervix (NIVIX). [PDF]

Front Oncol
Pathak P, Jo E, Hilsenbeck S, Anderson ML, Echeverria A, Sharma S, Sunde J, Hall T, Costales A, Hoppenot C, Ludwig M.   +10 more
europepmc   +1 more source

COMPUTATIONAL DRUG DESIGN AND MOLECULAR DYNAMICS OF PHENYL BENZAMIDE DERIVATIVES AS PARP-1 INHIBITORS FOR BREAST CANCER THERAPY

Pulla Prudvi Raj, Divya Jyothi Palati, Praveen Thaggikuppe Krishnamurthy, Gowramma Byran   +3 more
openalex   +2 more sources

Anti‐Cancer Effect of a New 5‐FU Derivative Containing Triazole‐Bearing Mannose (5‐FUD‐MAN) Against Human Breast Cancer Cells Through LC3B‐Mediated Cell Death

Journal of Biochemical and Molecular Toxicology, Volume 40, Issue 4, April 2026.
The anticancer activity of 5‐FU modified with mannose containing 1,2,3‐triazole compound in MCF‐7 breast cancer cells were revealed in this study. While 5‐FU caused cytotoxicity in both cancerous and healthy cells, 5‐FUD‐Man showed selective cytotoxicity.
Ebru Şanci, Azada Aliyeva, Buket Bakan, Mustafa Özkaraca, Erkan Halay, Kadir Ay, Tamer Karayildirim, N. Ulku Karabay Yavasoglu   +7 more
wiley   +1 more source

The Flavivirus NS3 Protein: Its Multifaceted Roles and Therapeutic Potential

Journal of Medical Virology, Volume 98, Issue 4, April 2026.
Abstract Mosquito‐borne flaviviruses are important human pathogenic viruses and can cause an array of symptoms ranging from asymptomatic to mild illness but can progress to severe disease conditions. Prominent members of the family Flaviviridae include Dengue virus, Zika virus, and West Nile virus, whose spread has increased globally due to the ...
Haejeong Lee, Hee Cho, Michaela U. Gack
wiley   +1 more source

Expert opinion on the management of anemia in prostate cancer patients receiving PARP inhibitors. [PDF]

Can Urol Assoc J
Hanna L, O'Dwyer R, Hamilou Z, Noonan K, Doucette S, Sridhar SS.   +5 more
europepmc   +1 more source

A Combination of Xanthohumol and Ursolic Acid in the Diet Leads to Synergistic Inhibition of Prostate Cancer Progression

Molecular Carcinogenesis, Volume 65, Issue 4, Page 508-522, April 2026.
ABSTRACT Prostate cancer (PCa) is the second most common cancer and second leading cause of cancer death for American men. Chemoprevention by using phytochemicals offers a promising approach to improve outcomes due to their ability to act on cancer cell metabolism and growth while maintaining low toxicity profiles.
Rachel Clark, Achinto Saha, G. Lavender Hackman, Chelsea A. Friedman, Ruggiero Gorgoglione, Stefano Tiziani, John DiGiovanni   +6 more
wiley   +1 more source

Efficacy and safety of PARP inhibitors monotherapy or combination therapy with anti-angiogenics in ovarian cancer: a network meta-analysis. [PDF]

Front Oncol
Liu Y, Ren T, Wang X, Wang Y, Tang L, Cao W.   +5 more
europepmc   +1 more source